Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry
Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oes...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2012-08, Vol.131 (3), p.558-569 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 569 |
---|---|
container_issue | 3 |
container_start_page | 558 |
container_title | International journal of cancer |
container_volume | 131 |
creator | Lærum, Ole Didrik Ovrebo, Kjell Skarstein, Arne Christensen, Ib Jarle Alpízar-Alpízar, Warner Helgeland, Lars Danø, Keld Nielsen, Boye Schnack Illemann, Martin |
description | Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas. |
doi_str_mv | 10.1002/ijc.26382 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3118798665</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3073977261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhwBdAllAPSKS149hJjtWK_tMCBUHhZk2cya6XJF7shHZP_ep42d1ygtNIM7_3njSPkJecHXPG0hO7NMepEkX6iEw4K_OEpVw-JpN4Y0nOhTogz0JYMsa5ZNlTcpDyQimZFRNyf-3dvHfBBmp7CjX2zoA3tncdBOoa2rpb9NRhcKsFzMfwls4hDN4l-xVCS5djbwbrokFf06ivLVD8Be0IA9a0WtPx-vRzYrtu7N3ChsGZBXZx-vVz8qSBNuCL3TwkX8_efZleJLOP55fT01lisiJLE0AuJfCsRFkaxAqVMMDAVCxreINKVUaC4SkCx6IQ0JQm5UyAhCxHhaU4JK-3vivvfo4YBr10o-9jpBacF3m5ecj_KJ6JCJZ5tqHebCnjXQgeG73ytgO_1pzpTSE6FqL_FBLZVzvHseqwfiD3DUTgaAdAMNA2Hnpjw19OMa5kySJ3suVubYvrfyfqy6vpPjrZKuKj8e5BAf6HVrnIpf724VzfXL0_-z67uNGfxG_tZ7OL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1433119745</pqid></control><display><type>article</type><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><creator>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</creator><creatorcontrib>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</creatorcontrib><description>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.26382</identifier><identifier>PMID: 21866548</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>adenocarcinoma ; Adenocarcinoma - chemistry ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Antigen-presenting cells ; Barrett Esophagus - metabolism ; Barrett Esophagus - pathology ; Barrett's esophagus ; Barrett's metaplasia ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Cancer ; Carcinogenesis ; Cardia ; Cells ; Esophageal cancer ; Esophageal Neoplasms - chemistry ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Esophagogastric Junction ; Esophagus ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunoenzyme Techniques ; Immunohistochemistry ; invasion ; Invasiveness ; Macrophages ; Macrophages - chemistry ; Male ; Medical prognosis ; Medical research ; Medical sciences ; Metaplasia ; Metastases ; Middle Aged ; Multivariate analysis ; Myofibroblasts - chemistry ; Neoplasm Invasiveness ; oesophagus ; Prognosis ; Proteolysis ; Receptors, Urokinase Plasminogen Activator - analysis ; Receptors, Urokinase Plasminogen Activator - immunology ; Stomach Neoplasms - chemistry ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - surgery ; Survival Rate ; Tumors ; U-Plasminogen activator ; uPAR</subject><ispartof>International journal of cancer, 2012-08, Vol.131 (3), p.558-569</ispartof><rights>Copyright © 2011 UICC</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 UICC.</rights><rights>Copyright Wiley Subscription Services, Inc. Aug 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</citedby><cites>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.26382$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.26382$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26016590$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21866548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lærum, Ole Didrik</creatorcontrib><creatorcontrib>Ovrebo, Kjell</creatorcontrib><creatorcontrib>Skarstein, Arne</creatorcontrib><creatorcontrib>Christensen, Ib Jarle</creatorcontrib><creatorcontrib>Alpízar-Alpízar, Warner</creatorcontrib><creatorcontrib>Helgeland, Lars</creatorcontrib><creatorcontrib>Danø, Keld</creatorcontrib><creatorcontrib>Nielsen, Boye Schnack</creatorcontrib><creatorcontrib>Illemann, Martin</creatorcontrib><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><title>International journal of cancer</title><addtitle>Int. J. Cancer</addtitle><description>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</description><subject>adenocarcinoma</subject><subject>Adenocarcinoma - chemistry</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigen-presenting cells</subject><subject>Barrett Esophagus - metabolism</subject><subject>Barrett Esophagus - pathology</subject><subject>Barrett's esophagus</subject><subject>Barrett's metaplasia</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer</subject><subject>Carcinogenesis</subject><subject>Cardia</subject><subject>Cells</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - chemistry</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Esophagogastric Junction</subject><subject>Esophagus</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunohistochemistry</subject><subject>invasion</subject><subject>Invasiveness</subject><subject>Macrophages</subject><subject>Macrophages - chemistry</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metaplasia</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Myofibroblasts - chemistry</subject><subject>Neoplasm Invasiveness</subject><subject>oesophagus</subject><subject>Prognosis</subject><subject>Proteolysis</subject><subject>Receptors, Urokinase Plasminogen Activator - analysis</subject><subject>Receptors, Urokinase Plasminogen Activator - immunology</subject><subject>Stomach Neoplasms - chemistry</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - surgery</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>U-Plasminogen activator</subject><subject>uPAR</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhwBdAllAPSKS149hJjtWK_tMCBUHhZk2cya6XJF7shHZP_ep42d1ygtNIM7_3njSPkJecHXPG0hO7NMepEkX6iEw4K_OEpVw-JpN4Y0nOhTogz0JYMsa5ZNlTcpDyQimZFRNyf-3dvHfBBmp7CjX2zoA3tncdBOoa2rpb9NRhcKsFzMfwls4hDN4l-xVCS5djbwbrokFf06ivLVD8Be0IA9a0WtPx-vRzYrtu7N3ChsGZBXZx-vVz8qSBNuCL3TwkX8_efZleJLOP55fT01lisiJLE0AuJfCsRFkaxAqVMMDAVCxreINKVUaC4SkCx6IQ0JQm5UyAhCxHhaU4JK-3vivvfo4YBr10o-9jpBacF3m5ecj_KJ6JCJZ5tqHebCnjXQgeG73ytgO_1pzpTSE6FqL_FBLZVzvHseqwfiD3DUTgaAdAMNA2Hnpjw19OMa5kySJ3suVubYvrfyfqy6vpPjrZKuKj8e5BAf6HVrnIpf724VzfXL0_-z67uNGfxG_tZ7OL</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Lærum, Ole Didrik</creator><creator>Ovrebo, Kjell</creator><creator>Skarstein, Arne</creator><creator>Christensen, Ib Jarle</creator><creator>Alpízar-Alpízar, Warner</creator><creator>Helgeland, Lars</creator><creator>Danø, Keld</creator><creator>Nielsen, Boye Schnack</creator><creator>Illemann, Martin</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20120801</creationdate><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><author>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>adenocarcinoma</topic><topic>Adenocarcinoma - chemistry</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigen-presenting cells</topic><topic>Barrett Esophagus - metabolism</topic><topic>Barrett Esophagus - pathology</topic><topic>Barrett's esophagus</topic><topic>Barrett's metaplasia</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer</topic><topic>Carcinogenesis</topic><topic>Cardia</topic><topic>Cells</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - chemistry</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Esophagogastric Junction</topic><topic>Esophagus</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunohistochemistry</topic><topic>invasion</topic><topic>Invasiveness</topic><topic>Macrophages</topic><topic>Macrophages - chemistry</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metaplasia</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Myofibroblasts - chemistry</topic><topic>Neoplasm Invasiveness</topic><topic>oesophagus</topic><topic>Prognosis</topic><topic>Proteolysis</topic><topic>Receptors, Urokinase Plasminogen Activator - analysis</topic><topic>Receptors, Urokinase Plasminogen Activator - immunology</topic><topic>Stomach Neoplasms - chemistry</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - surgery</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>U-Plasminogen activator</topic><topic>uPAR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lærum, Ole Didrik</creatorcontrib><creatorcontrib>Ovrebo, Kjell</creatorcontrib><creatorcontrib>Skarstein, Arne</creatorcontrib><creatorcontrib>Christensen, Ib Jarle</creatorcontrib><creatorcontrib>Alpízar-Alpízar, Warner</creatorcontrib><creatorcontrib>Helgeland, Lars</creatorcontrib><creatorcontrib>Danø, Keld</creatorcontrib><creatorcontrib>Nielsen, Boye Schnack</creatorcontrib><creatorcontrib>Illemann, Martin</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lærum, Ole Didrik</au><au>Ovrebo, Kjell</au><au>Skarstein, Arne</au><au>Christensen, Ib Jarle</au><au>Alpízar-Alpízar, Warner</au><au>Helgeland, Lars</au><au>Danø, Keld</au><au>Nielsen, Boye Schnack</au><au>Illemann, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int. J. Cancer</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>131</volume><issue>3</issue><spage>558</spage><epage>569</epage><pages>558-569</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21866548</pmid><doi>10.1002/ijc.26382</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-7136 |
ispartof | International journal of cancer, 2012-08, Vol.131 (3), p.558-569 |
issn | 0020-7136 1097-0215 |
language | eng |
recordid | cdi_proquest_journals_3118798665 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library |
subjects | adenocarcinoma Adenocarcinoma - chemistry Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery Adult Aged Aged, 80 and over Antigen-presenting cells Barrett Esophagus - metabolism Barrett Esophagus - pathology Barrett's esophagus Barrett's metaplasia Biological and medical sciences Biomarkers, Tumor - analysis Cancer Carcinogenesis Cardia Cells Esophageal cancer Esophageal Neoplasms - chemistry Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Esophagogastric Junction Esophagus Female Gastroenterology. Liver. Pancreas. Abdomen Humans Immunoenzyme Techniques Immunohistochemistry invasion Invasiveness Macrophages Macrophages - chemistry Male Medical prognosis Medical research Medical sciences Metaplasia Metastases Middle Aged Multivariate analysis Myofibroblasts - chemistry Neoplasm Invasiveness oesophagus Prognosis Proteolysis Receptors, Urokinase Plasminogen Activator - analysis Receptors, Urokinase Plasminogen Activator - immunology Stomach Neoplasms - chemistry Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - surgery Survival Rate Tumors U-Plasminogen activator uPAR |
title | Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20in%20adenocarcinomas%20of%20lower%20oesophagus,%20gastro-oesophageal%20junction%20and%20cardia%20evaluated%20by%20uPAR-immunohistochemistry&rft.jtitle=International%20journal%20of%20cancer&rft.au=L%C3%A6rum,%20Ole%20Didrik&rft.date=2012-08-01&rft.volume=131&rft.issue=3&rft.spage=558&rft.epage=569&rft.pages=558-569&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.26382&rft_dat=%3Cproquest_cross%3E3073977261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1433119745&rft_id=info:pmid/21866548&rfr_iscdi=true |